BKV Corporation (NYSE:BKV – Get Free Report) has received an average rating of “Buy” from the eight analysts that are covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $25.88.
A number of brokerages have recently commented on BKV. Evercore ISI began coverage on shares of BKV in a research report on Monday, October 21st. They issued an “outperform” rating and a $24.00 price objective for the company. KeyCorp began coverage on shares of BKV in a report on Monday, October 21st. They set an “overweight” rating and a $23.00 target price for the company. Susquehanna lifted their target price on shares of BKV from $24.00 to $25.00 and gave the stock a “positive” rating in a report on Wednesday, November 13th. Barclays began coverage on shares of BKV in a report on Monday, October 21st. They set an “overweight” rating and a $24.00 target price for the company. Finally, Citigroup began coverage on shares of BKV in a report on Monday, October 21st. They set a “buy” rating and a $29.00 target price for the company.
Read Our Latest Research Report on BKV
Insider Activity
BKV Stock Down 0.7 %
Shares of BKV opened at $23.25 on Tuesday. The company has a 50-day moving average price of $19.93. BKV has a one year low of $17.39 and a one year high of $24.03.
BKV Company Profile
BKV Corporation engages in the acquisition, operation, and development of natural gas and NGL properties. It is also involved in the gathering, processing, and transportation of natural gas. The company was founded in 2015 and is based in Denver, Colorado with additional offices in Tunkhannock, Pennsylvania and Fort Worth, Texas.
Recommended Stories
- Five stocks we like better than BKV
- What is the Nikkei 225 index?
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Bank Stocks – Best Bank Stocks to Invest In
- Texas Instruments: The Old-School Tech Titan Still Delivering
- What Do S&P 500 Stocks Tell Investors About the Market?
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for BKV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BKV and related companies with MarketBeat.com's FREE daily email newsletter.